Growing interest of non-profit and private organizations are displaying growing interest towards the development of drugs and therapeutic treatments for frontotemporal disorders (FTD). This development can be attributed to rising incidences of mental health issues such as dementia that are associated to the higher rates of FTD occurrences among the world’s population.
As a result, support for clinical trials for testing improved treatments to slow down, prevent or completely stop FTD and progression of other mental diseases has grown rapidly. With constantly growing incidences of dementia, and improving training for healthcare professionals, the adoption of frontotemporal disorders treatment is anticipated to grow at a steady CAGR of more than 4.5%, as estimated by Future Market Insights in a recent report on the global frontotemporal disorders treatment market.
Drug Development Grants by Non-Profits Drives New Treatment Options
Increasingly, non-profit organizations such as the Alzheimer Discovery Foundation (ADDF), Association for Frontotemporal Degeneration (AFTD), Tau Consortium Organization, Bluefield Project Organization, and CurePSP, Inc. are emphasizing on increasing support to drug development for FTD treatment. This can be attributed to the lack of effort taken by the pharmaceutical sector towards the research and development of FTD treatment.
For example, The Association for Frontotemporal Degeneration has set up an Accelerating Drug Discovery for FTD program that aims towards the identification of cures that involve research on peptides, oligonucleotides, gene therapy, and antibodies, with funding for individual researchers up to $150,000.
The offer focuses on the identification and validation of targets, development of specialized assays, and high content screening for the optimization of disease modifying compounds, and testing biologics.
Similarly, the Alzheimer’s Drug Discovery Foundation, has also created a support program called The Treat FTD Fund that supports research efforts up to 3 years, ranging between $500,000 and $2,000,000, for research bodies based in the United States. This is anticipated to help in the running of clinical trials to recognize the ideal approach towards the use of repurposed or novel medications.
Rising Awareness about Frontotemporal Dementia Create Demand
Frontotemporal dementia is considered to be a rare disease. FTD afflicts up to 40,000 people every year in the U.S. alone and accounts for up to 20% of all dementia cases. As a result, the treatments for FTD come under the regulations of the Orphan Drug Act of 1983 in the US. Moreover, similar kinds of regulations have been imposed on the treatment across Europe.
This gives researchers a number of mechanisms of funding and monetary incentives for drug developing companies to get the approval of orphan medications. Orphan drug designation for frontotemporal disorders permits the researchers to conduct clinical trials along, which are given higher priority by certifying bodies, along with a standard reduction in fees.
In addition, such regulations also provide the significant advantages of having a fast track status to bring approved remedies into the market without delay. This is a key factor that is anticipated to propel the growth of the market for frontotemporal disorders in the years to come.
For additional information on the frontotemporal disorders treatment market, click here.